DK1381681T3 - NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser - Google Patents

NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser

Info

Publication number
DK1381681T3
DK1381681T3 DK02720271T DK02720271T DK1381681T3 DK 1381681 T3 DK1381681 T3 DK 1381681T3 DK 02720271 T DK02720271 T DK 02720271T DK 02720271 T DK02720271 T DK 02720271T DK 1381681 T3 DK1381681 T3 DK 1381681T3
Authority
DK
Denmark
Prior art keywords
variants
hgf
fragment
applications
growth factor
Prior art date
Application number
DK02720271T
Other languages
English (en)
Inventor
Ermanno Gherardi
Daniel Lietha
Thomas Leon Blundell
Dimitry Yurievich Chirgadze
Original Assignee
Medical Res Council
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Cambridge Entpr Ltd filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1381681T3 publication Critical patent/DK1381681T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DK02720271T 2001-04-27 2002-04-29 NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser DK1381681T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110430.6A GB0110430D0 (en) 2001-04-27 2001-04-27 Protein variants and uses thereof
PCT/GB2002/001941 WO2002088354A1 (en) 2001-04-27 2002-04-29 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use

Publications (1)

Publication Number Publication Date
DK1381681T3 true DK1381681T3 (da) 2007-10-29

Family

ID=9913640

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02720271T DK1381681T3 (da) 2001-04-27 2002-04-29 NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser

Country Status (11)

Country Link
US (3) US7179786B2 (da)
EP (1) EP1381681B1 (da)
JP (2) JP4637452B2 (da)
AT (1) ATE368741T1 (da)
AU (1) AU2002251337B2 (da)
CA (1) CA2440775C (da)
DE (1) DE60221510T2 (da)
DK (1) DK1381681T3 (da)
ES (1) ES2291460T3 (da)
GB (1) GB0110430D0 (da)
WO (1) WO2002088354A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20050107296A1 (en) * 2001-10-31 2005-05-19 Institut Des Vaisseaux Et Du Sang Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
US7563570B2 (en) 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US20090215686A1 (en) * 2007-03-05 2009-08-27 Huaqiang Eric Xu Nk1-based polypeptides and related methods
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
WO2011103382A2 (en) * 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
WO2013037521A1 (en) 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2013037520A1 (en) 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
CA2973300C (en) 2015-01-21 2024-03-19 Universite Des Sciences Et Technologies De Lille-Lille 1 Met receptor agonist proteins
BR112018076306A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
KR20190107097A (ko) 2017-01-20 2019-09-18 마젠타 테라퓨틱스 인코포레이티드 Cd137+ 세포의 고갈을 위한 조성물 및 방법
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594115A (en) * 1990-04-09 1997-01-14 Pharmacia & Upjohn Company Process of purifying recombinant proteins and compounds useful in such process
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof

Also Published As

Publication number Publication date
US7795214B2 (en) 2010-09-14
JP4637452B2 (ja) 2011-02-23
US7179786B2 (en) 2007-02-20
AU2002251337B2 (en) 2007-08-02
DE60221510T2 (de) 2008-04-17
US8232258B2 (en) 2012-07-31
US20080167224A1 (en) 2008-07-10
GB0110430D0 (en) 2001-06-20
JP2011045370A (ja) 2011-03-10
US20040236073A1 (en) 2004-11-25
EP1381681B1 (en) 2007-08-01
DE60221510D1 (de) 2007-09-13
ES2291460T3 (es) 2008-03-01
US20110021612A1 (en) 2011-01-27
WO2002088354A1 (en) 2002-11-07
CA2440775C (en) 2013-02-26
EP1381681A1 (en) 2004-01-21
CA2440775A1 (en) 2002-11-07
JP2004532032A (ja) 2004-10-21
ATE368741T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DK1381681T3 (da) NK1-fragmentet af hepatocytvækstfaktor/spredningsfaktor (HGF/SF) og varianter deraf og deres anvendelser
DK1390066T3 (da) Vaccinesammensætning
DE60232987D1 (de) Injizierbare depotzusammensetzungen
ATE319666T1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
NO20021116D0 (no) Ny sammensetning
DE60042565D1 (de) Feuerlöschzusammensetzung
NO20021115L (no) Ny sammensetning
DK1524981T3 (da) Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
NO20041258L (no) Intraoralt desintegrerende Valdecoxibsammensetninger.
EE200300589A (et) Ravimkoostised
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
FI20022128A (fi) Farmaseuttinen koostumus
DE60036959D1 (de) Tensidzusammensetzungen, verbesserungsmittel enthaltend
FR2787721B1 (fr) Compositions extinctrices
NO20013441D0 (no) Sammensetninger som har forbedret stabilitet
DE10290726D2 (de) Strebsteuerung für den Strebausbau
BR0206044B1 (pt) Composição alvejante
DE60202519D1 (de) Fungizide zusammensetzungen auf der basis von pyridylmethylbenzamid-derivaten und propamocarb
DE60205148D1 (de) Biopestizid-Zusammensetzungen
DE50114951D1 (de) Stabilisatorzusammensetzung
SE9904404L (sv) Ny komposition
NO20014586D0 (no) Resorcinol sammensetninger
DE60005826D1 (de) Fungizide zusammensetzungen
DE60015133D1 (de) Synergistische zusammensetzung von bioziden